Company intelligence / Profile preview

Infusicare

London, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Infusicare generated C$9.3M in revenue and C$400,000 in gross profit (latest fiscal year before acquisition); offered biologic and specialty drugs for immune-mediated conditions, notably rheumatoid arthritis.

Therapeutic areas: Immunology
Modalities: Biologic drugsSmall molecule drugs
Industry: Non-Academic Healthcare

Partnerships

Mednow

Beyond the preview

Go deeper on Infusicare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infusicare.

Explore the full profile